T H 2 cells are classically thought to drive the development of asthma through the production of IL-4, IL-5, IL-9 and IL-13 (refs. 1,2), but recent evidence suggests that the T H 17-derived cytokine, IL-17A, may also have a key role [3] [4] [5] . T H 17 cells make up a pro-inflammatory subset of T helper cells that is defined by its production of IL-17A, IL-17F and IL-22, and T H 17 cells are thought to have evolved to aid in host defense against bacteria and fungi 6 . Elevated concentrations of IL-17A have been found in the serum, sputum and bronchoalveolar lavage fluids (BAL) of patients with asthma, and the IL-17A concentration found at these sites positively correlates with asthma severity in these patients 7, 8 . Furthermore, genetic association studies in patients with asthma have identified variations in several genes that are key for T H 17 cell differentiation, including those encoding transforming growth factor β1 (TGF-β1) [9] [10] [11] , IL-1β 12 and IL-6 (ref. 13) . Although T H 17 cells seem to have a role in the development of allergic asthma, the mechanisms controlling their development in the lung are less clear.
Initial studies of T H 17 differentiation showed that IL-6 and TGF-β together are sufficient for the conversion of naive T cells into T H 17 cells 14, 15 . The combination of T cell receptor (TCR) stimulation and the presence of TGF-β induces the synthesis of the retinoic-acidrelated orphan receptor γ (ROR γ t ) transcription factor, which is specific for the T H 17 lineage among the T cell subsets 16 . IL-6 signaling triggers binding of signal transducer and activator of transcription 3 (STAT3) to the ROR γt locus, resulting in a positive feedback loop that drives T cell differentiation towards the T H 17 lineage 17 . More recent studies have shown that other stimuli, such as IL-1β, IL-21, IL-23, commensal-bacteria-derived ATP, segmented filamentous bacterium and activators of the aryl hydrocarbon receptor, also promote differentiation of T H 17 cells or expand T H 17 populations [18] [19] [20] [21] [22] . However, TGF-β is a required factor for T H 17 cell development in both humans and mice, and its regulation is probably a crucial mechanism that controls the differentiation of T H 17 cells 22, 23 . TGF-β is produced as part of a latent complex and needs to be activated to bind TGF-β receptors 24 . We recently reported that integrin αvβ8 expressed on dendritic cells activates latent TGF-β and mediates the differentiation of both adaptive regulatory T cells and T H 17 cells in the colon 25, 26 . However, the relevance of this pathway for T cell differentiation in the lung and in the development of allergic airway disease has not been previously investigated.
T H 17-derived cytokines promote inflammation by a variety of mechanisms. IL-17A enhances neutrophil recruitment by stimulating bone marrow stromal cells to produce granulocyte colony-stimulating factor (G-CSF), which augments granulopoiesis and the conversion of neutrophil progenitors from CD34 + cells 27 . IL-17A also induces neutrophil recruitment by stimulating the expression of chemokine IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction Emerging evidence suggests that the T helper 17 (T H 17) subset of ab T cells contributes to the development of allergic asthma. In this study, we found that mice lacking the avb8 integrin on dendritic cells did not generate T H 17 cells in the lung and were protected from airway hyper-responsiveness in response to house dust mite and ovalbumin sensitization and challenge. Because loss of T H 17 cells inhibited airway narrowing without any obvious effects on airway inflammation or epithelial morphology, we examined the direct effects of T H 17 cytokines on mouse and human airway smooth muscle function. Interleukin-17A (IL-17A), but not IL-17F or IL-22, enhanced contractile force generation of airway smooth muscle through an IL-17 receptor A (IL-17RA)-IL-17RC, nuclear factor k light-chain enhancer of activated B cells (NF-kB)-ras homolog gene family, member A (RhoA)-Rho-associated coiled-coil containing protein kinase 2 (ROCK2) signaling cascade. Mice lacking integrin avb8 on dendritic cells showed impaired activation of this pathway after ovalbumin sensitization and challenge, and the diminished contraction of the tracheal rings in these mice was reversed by IL-17A. These data indicate that the IL-17A produced by T H 17 cells contributes to allergen-induced airway hyper-responsiveness through direct effects on airway smooth muscle.
(C-X-C motif) ligand 1 (CXCL1), CXCL2, CXCL5 and CXCL8 in epithelial cells 28 . IL-17A promotes antibody isotype class switching in B cells and stimulates T H 1-type immune responses by inducing macrophages to secrete 30) . Although IL-17A is generally thought to have a pro-inflammatory role in asthma through the enhancement of neutrophil recruitment, additional roles for this and other T H 17-derived cytokines in the disease remain largely unexplored.
In this study, we began by determining the role of integrin αvβ8 expressed on dendritic cells in a mouse model of allergic airway disease. Notably, we observed that the mice in this model were protected from airway hyper-responsiveness (AHR) without any changes in lung inflammation and found that this protection correlated with a near-complete absence of T H 17 cells in the lung. We therefore tested cytokines produced by T H 17 cells for their ability to directly stimulate contractile responses in airway smooth muscle (ASM) and found that treatment of mouse ASM cells with IL-17A enhanced tracheal ring contraction after stimulation with methacholine (MCh) or potassium chloride (KCl). These findings identify a key role for the αvβ8 integrin on dendritic cells of generating pathogenic T H 17 cells in allergic asthma and show that IL-17A released from these cells contributes to airway hyper-responsiveness by directly increasing the contractility of ASM.
RESULTS

Itgb8 flox/flox
; CD11c-Cre mice are protected from AHR To determine the role of integrin αvβ8 on dendritic cells in allergic airway disease, we sensitized and challenged control mice or mice lacking integrin αvβ8 on their dendritic cells (Itgb8 flox/flox ; CD11c-Cre mice), as we previously described 25, 26 . OVA sensitization and challenge increased AHR in response to the bronchoconstrictor acetylcholine in control mice, but Itgb8 flox/flox ; CD11c-Cre mice were significantly protected from allergen-induced AHR (Fig. 1a) . To determine the mechanism for the diminished AHR seen in mice had similar numbers of mucus-secreting cells, as determined by periodic acid-Schiff (PAS) staining, as well as similar numbers of macrophages, eosinophils, lymphocytes and polymorphonuclear cells in the BAL fluid ( Fig. 1b-d) . We also examined whether Itgb8 flox/flox ; CD11c-Cre mice were protected from AHR in the house dust mite (HDM) asthma model. Itgb8 flox/flox ; CD11c-Cre mice had significantly (P < 0.05) reduced AHR after HDM sensitization and challenge when compared to control mice ( Supplementary Fig. 1a ). Intranasal delivery of IL-13 is known to provoke AHR, mucus production and leukocyte accumulation in the lungs of mice 2, 31 . Therefore, we tested whether Itgb8 flox/flox ; CD11c-Cre mice were capable of developing AHR after intranasal administration of IL-13 to their lungs. Intranasal IL-13 increased similar amounts of AHR in both Itgb8 flox/flox ; CD11c-Cre and control mice, indicating that Itgb8 flox/flox ; CD11c-Cre mice have the capacity to develop AHR ( Supplementary Fig. 1b ).
Because AHR in response to OVA or HDM requires an adaptive immune response, and our previous work implicated integrin αvβ8 on dendritic cells in the regulation of CD4 + T cell differentiation, we tested the recall response of lymphocytes to OVA and characterized the CD4 + T cell subsets in the lungs of the mice from the two groups. Control and Itgb8 flox/flox ; CD11c-Cre mice had similar lymphocyte recall responses to OVA (Fig. 1e) . T H 2 cells, identified by intracellular flow cytometry for IL-13, were increased similarly in response to OVA in control and Itgb8 flox/flox ; CD11c-Cre mice (Fig. 1f,g ). We found less Foxp3 + adaptive regulatory T cells in the lungs of Itgb8 flox/flox ; CD11c-Cre mice compared to control mice before OVA sensitization and challenge, but there was no significant difference in the percentage of regulatory T cells in the lungs of Itgb8 flox/flox ; CD11c-Cre mice compared to control mice induced in response to OVA (Fig. 1f,g ). OVA sensitization and challenge increased the percentage of T H 17 cells, marked by expression of IL-17A and CD4, in the lungs of control mice, but Itgb8 flox/flox ; CD11c-Cre mice had a near absence of T H 17 cells before and after OVA sensitization and challenge. Notably, the inability to generate IL-17A-producing T cells in Itgb8 flox/flox ; CD11c-Cre mice was restricted to the T H 17 lineage, as the number of IL-17A-producing γδ T cells in these mice was comparable to that seen in the control mice (Fig. 1f,g ). This finding suggests that Itgb8 flox/flox ; CD11c-Cre mice may be protected from AHR through a specific defect in the generation of T H 17 cells.
IL-17A enhances ASM contraction IL-13 and tumor necrosis factor α (TNF-α) have been reported to act directly on ASM to enhance AHR, and we wondered whether IL-17 cytokines might also act in this way 32, 33 . We detected mRNA for both IL-17 receptor A (IL-17RA) and IL-17RC in cultured primary ASM cells from wild-type C57BL/6 mice (Fig. 2a) . We then determined the effects of IL-17A on the contractile force generated by mouse tracheal rings stimulated with MCh or depolarization with KCl and on the degree of airway narrowing induced by MCh in agarose-filled lung slices. IL-17A treatment alone had no effects on contraction when applied for 15 min directly to tracheal rings in the organ bath (data not shown). However, incubation with IL-17A for 12 h significantly enhanced both MCh-and KCl-induced tracheal ring contraction (Fig. 2b) and MCh-induced airway narrowing in the lung slices (Fig. 2c,d ). To determine whether IL-17A was acting on the smooth muscle or the epithelium, we denuded the epithelium from the tracheal rings and then measured the effects of IL-17A on their contraction. As others have reported, epithelial removal enhanced the amount of force generated in response to MCh and KCl (Supplementary Fig. 2 ) 34, 35 . In tracheal rings completely denuded of epithelium, IL-17A increased the contraction to a similar degree as it did in intact tracheal rings, indicating that IL-17A acts directly on smooth muscle to enhance contraction. We next determined whether IL-17A also enhanced ASM contraction in human tissue. In isolated human bronchi, a 12-h pretreatment with IL-17A significantly increased the contraction of human bronchi in response to MCh and KCl (Fig. 2e) . These data suggest that IL-17A acts on ASM in mice and humans to enhance contractile responses.
To test whether IL-17A was interacting directly or indirectly with the ASM, we added atropine, a muscarinic receptor antagonist, to tracheal rings from wild-type C57BL/6 mice to determine whether IL-17A augmented contractile responses through modulation of MCh signaling. Atropine completely prevented contractile responses triggered by MCh in tracheal rings pretreated with IL-17A but had no effect on the contractile responses stimulated by KCl (Fig. 3a) . We then confirmed that enhanced contraction was a result of IL-17A and not of other contaminants in our IL-17A preparation. Concurrent incubation with IL-17A and antibodies that block IL-17A activity prevented the enhanced contraction seen with IL-17A alone in response to MCh and KCl (Fig. 3b) . TNF-α is known to enhance ASM npg contraction, and we wondered whether pretreatment with IL-17A was indirectly stimulating contractile responses through release of TNF-α 33 . Addition of TNF-α-blocking antibodies had no effect on the enhanced tracheal ring contraction induced by IL-17A (Fig. 3c) .
Preincubation with TNF-α increased tracheal ring contraction in response to both MCh and KCl, and this enhancement was prevented with the addition of TNF-α-blocking antibodies, confirming that the TNF-α-blocking antibodies were functional (Fig. 3d) . These data indicate that IL-17A augments tracheal ring contraction through direct effects on ASM.
IL-17A stimulates contraction through NF-kB, RhoA and ROCK2 Contractile force in ASM is generated through actin-myosin crossbridging and is regulated by myosin light chain (MLC) phosphorylation 36 . To determine whether IL-17A enhances ASM contraction through regulation of MLC phosphorylation, we measured MLC phosphorylation with an antibody specific to phosphorylated Ser19 of MLC. IL-17A markedly increased MCh-induced Ser19 phosphorylation of MLC (Fig. 4a,b) . IL-17A has been reported to activate of the NF-κB pathway 37, 38 . To determine whether IL-17A enhanced ASM contraction through activation of NF-κB, we measured NF-κB activation in tracheal ASM from wild-type C57BL/6 mice after treatment with 100 ng ml −1 IL-17A. IL-17A rapidly decreased the cytosolic concentration of NF-κB and induced the nuclear translocation of NF-κB, indicating that IL-17A activates NF-κB in tracheal rings at a concentration that also promotes enhanced contraction (Fig. 4c,d ). (Fig. 4e) . NF-κB is known to regulate the expression of the small GTPase RhoA and its effector kinases ROCK1 and ROCK2 (refs. 39,40) . The RhoA-ROCK signaling pathway is a key mediator of ASM contraction 36, 41 . Treatment of tracheal rings with IL-17A increased the expression of RhoA and ROCK2 but not ROCK1 (Fig. 4f,g ). ROCK2 regulates MLC phosphorylation through phosphorylation of the myosin-binding subunit of myosin phosphatase (MYPT1), which inhibits the activity of myosin phosphatase 42 . IL-17A treatment of ASM stimulated MYPT1 phosphorylation (Fig. 4f,g ).
To determine whether the RhoA-ROCK2-MYPT1 pathway is required for IL-17A-mediated enhanced contraction, we blocked ROCK activity with the small-molecule inhibitor Y-27632. Y-27632 inhibited the IL-17A-mediated enhancement of tracheal ring contraction in a dose-dependent manner (Fig. 4h) . To test whether stimulation of RhoA and ROCK2 expression was mediated through NF-κB, we also measured the expression of these proteins after treatment of tracheal rings with BAY 11-7082. Pretreatment of tracheal rings with BAY 11-7082 inhibited the effects of IL-17A on the expression of RhoA and decreased the phosphorylation of MYPT1 and MLC after stimulation with MCh (Fig. 4i) . Treatment with Y-27632 under similar conditions had no effect on nuclear NF-κB translocation or RhoA expression but did block the phosphorylation of MYPT1 and MLC (Fig. 4i) . We also determined whether IL-17A regulated ASM contraction through modulation of calcium signaling. Treatment of lung slices with IL-17A had no effect on MCh-induced calcium-wave oscillation amplitude or frequency (Supplementary Fig. 3) . Collectively, these data indicate that IL-17A enhances the contractile responses of ASM through the activation of NF-κB and the subsequent induction of RhoA and ROCK2 expression. (e) Pulmonary resistance measurements after administration of acetylcholine in control and Il17rc −/− mice immunized and intranasally challenged with OVA or saline. *P < 0.05 in OVA-treated control mice compared to OVA-treated Il17rc −/− mice (n = 9). Student's t test was used to calculate statistical significance throughout this figure, except for the analysis of pulmonary resistance measurements, in which a t test with Bonferroni adjustment was used. We next explored whether other cytokines produced by T H 17 cells promote ASM contraction. Incubation of tracheal rings from wildtype C57BL/6 mice with IL-17F or IL-22 for 12 h at a range of doses (30-300 ng ml −1 ) had no significant effect on MCh-or KCl-induced contractile responses (Fig. 5a,b) . In contrast, incubation with IL-17A dose-dependently increased MCh-and KCl-induced force generation (Fig. 5b) . Treatment with 100 ng ml −1 IL-17F or 100 ng ml −1 IL-22 followed by stimulation with MCh also had no effect on MLC phosphorylation, whereas IL-17A at this dose triggered a substantial increase in MLC phosphorylation (Fig. 5c) . IL-17A and IL-17F both bind to the IL-17RA-IL-17RC heterodimer 43 . Despite this, administration of 300 ng ml −1 IL-17F had no effect on ASM contractile responses. Therefore, we confirmed that IL-17A enhanced ASM contraction through binding to IL-17RA and IL-17RC. IL-17A did not enhance the contractile responses in tracheal rings isolated from mice deficient in IL-17RC after stimulation with MCh and KCl (Fig. 5d) . Mice deficient in IL-17RC were also protected from AHR in the OVA sensitization and challenge model of allergic asthma, which provides further evidence that IL-17A promotes the development of AHR in this model (Fig. 5e) .
To determine whether mice lacking integrin αvβ8 on their dendritic cells were protected from AHR through impaired activation of the NF-κB-RhoA-ROCK2 signaling cascade in response to IL-17A, we studied the activation of this pathway in OVA-challenged control and Itgb8 flox/flox ; CD11c-Cre mice. OVA sensitization and challenge induced a robust increased the amount of nuclear NF-κB, RhoA, ROCK2, phosphorylated MYPT1 (p-MYPT1) and p-MLC in ASM dissected from control mice but had substantially reduced effects on each of these endpoints in ASM from Itgb8 flox/flox ; CD11c-Cre mice (Fig. 6a) . Tracheal rings from OVA-sensitized and OVA-challenged Itgb8 flox/flox ; CD11c-Cre mice also had impaired contractile responses to both MCh and KCl (Fig. 6b) . To test whether a lack of IL-17A was responsible for these impaired contractile responses, we incubated tracheal rings from OVA-sensitized and OVA-challenged control and Itgb8 flox/flox ; CD11c-Cre mice with IL-17A. Preincubation of tracheal rings from OVA-sensitized and OVA-challenged Itgb8 flox/flox ; CD11c-Cre mice with IL-17A enhanced MCh-induced force generation in a dose-dependent manner to the amounts seen in control mice (Fig. 6c) . IL-17A preincubation of tracheal rings from OVA-sensitized and OVA-challenged control mice had minimal effects on contractility, possibly because these tissues had already been exposed to IL-17A in vivo. These data suggest that mice lacking integrin αvβ8 on their dendritic cells are protected from AHR as a consequence of reduced exposure of ASM to IL-17A.
DISCUSSION
A growing body of evidence implicates T H 17 cells and their associated cytokines in allergic asthma, especially in severe cases in which inflammation is predominantly driven by neutrophils 3, 4 . The data from this study indicate a previously unidentified mechanism for T H 17 cells in asthma pathogenesis. We show that IL-17A enhances the contractile response of ASM to MCh and KCl. The IL-17 cytokine family signals through heterodimeric complexes of IL-17RA and IL-17RE, and IL-17A and IL-17F are known to bind the IL-17RA-IL-17RC heterodimer in other tissues 28 . It was somewhat surprising to us that IL-17F, which, like IL-17A, can ligate IL-17RA-IL-17RC heterodimers, did not affect ASM contractility over a range of concentrations that were sufficient to produce the effects of IL-17A. We suspect that this result reflects the lower affinity of IL-17F for these receptors 43 . The NF-κB transcription factor is a major target of pro-inflammatory cytokines, and we found here that IL-17A causes a robust activation of NF-κB after stimulation of ASM by MCh. Because the primary phenotype we observed after IL-17A treatment was enhanced contraction, we looked for NF-κB target genes that would modulate ASM contraction. IL-17A treatment increased RhoA and ROCK2 expression, which are two prominent regulators of MLC phosphorylation and subsequent smooth muscle contraction 36 . Several groups have reported in studies of smooth muscle that activation of RhoA stimulates ROCK2 to phosphorylate MYPT1 [44] [45] [46] . This pathway was also stimulated in ASM of OVA-sensitized and OVAchallenged mice and was impaired in mice lacking integrin αvβ8 on their dendritic cells. Further, reduced tracheal ring contraction in OVA-sensitized and OVA-challenged mice lacking integrin αvβ8 on their dendritic cells could be completely restored by ex vivo IL-17A treatment. Together, these data suggest that protection from AHR in mice lacking integrin αvβ8 on their dendritic cells results from impaired IL-17A signaling. Because these mice had a near absence of pulmonary IL-17A-producing αβ T cells (T H 17), but had similar numbers of IL-17A-producing γδ T cells as control mice before and after OVA sensitization and challenge, our data suggest a model in which the IL-17A produced by T H 17 cells acts on ASM to induce AHR.
T H 17 cells and IL-17A have been implicated in several mouse models of asthma, although some of the data from these models are conflicting. Adoptive transfer of antigen-specific TCR transgenic T cells polarized in vitro to the T H 17 phenotype into antigenchallenged mice enhances AHR, as does pulmonary administration of an IL-17A-overexpressing adenovirus 47 . Further, as we observed in this study with IL-17RC-deficient mice, IL-17RA-deficient mice have been reported to show substantial protection from AHR in an OVA sensitization and challenge model of allergic asthma 48 . However, that same previous study found that neutralization of IL-17A at the time of OVA challenge exacerbated AHR and that local administration of IL-17A reduced eosinophilia and AHR. Another study using a similar model showed impaired induction of AHR in IL-17A-deficient mice crossed with OT-II TCR transgenic mice 49 . In several other studies, neutralization of IL-17A with antibodies or administration of exogenous IL-17A yielded mixed effects on allergen-induced AHR, but the preponderance of evidence supports a key role for IL-17A in allergic airway inflammation [50] [51] [52] [53] . Notably, the relative contributions of various cells and cytokines to models of allergic asthma can differ among inbred strains of mice, which might be one explanation for the apparently conflicting reports about the contributions of IL-17 to allergic asthma. Because we performed our study described here in C57BL/6 mice, we cannot be certain that the same effects would be seen in other strains (for example, BALB/c mice) in which T H 2 cytokines have more potent effects. IL-17A was recently shown to act synergistically with IL-13 to enhance AHR in the A/J mouse strain, whereas the C3H/HeJ mouse strain is naturally protected from AHR through decreased production of IL-17A 5 . Indeed, we and others have previously reported that inhibition of IL-13 can potently inhibit AHR in models of allergic asthma and that overexpression or administration of IL-13 is sufficient to induce AHR, in part through direct effects of IL-13 on airway epithelial cells. Based on the results of this study, we suspect that transgenic or intranasal administration of IL-13 results in higher concentrations of IL-13 than those released in the context of allergen challenge and that IL-17 may not be required for the development of AHR under these circumstances. Although inhibitor studies have confirmed that secreted IL-13 contributes to the development of allergen-induced AHR 54,55 , our results suggest that the small amounts npg of IL-13 released in response to allergen challenge are not sufficient to induce AHR but, rather, require the additional effect of IL-17.
The results of this study provide several new insights into how T H 17 cells and T H 17 cytokines contribute to the development of allergic asthma and, thus, identify a number of new potential therapeutic targets. Our results identify integrin αvβ8 as a crucial upstream activator that is essential for T H 17 cell generation in allergic airway disease. We also show that loss of this integrin on dendritic cells markedly inhibits T H 17 cell generation without having any effects on the IL-17A-producing γδ T cells, suggesting that it might be possible to inhibit this T H 17 induction without eliminating the key role of IL-17A-producing γδ T cells in the pulmonary defense against bacterial and fungal pathogens. Furthermore, our findings are the first, to our knowledge, to show that IL-17A, but not IL-17F or IL-22, can contribute to allergic asthma by directly enhancing the contractile responses of ASM cells through a pathway that involves activation of NF-κB and induction of RhoA and ROCK2 expression. The αvβ8 integrin, IL-17A, NF-κB and downstream effectors of this pathway could thus all be attractive targets for improved treatment of allergic asthma.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
